WESPAC Advisors SoCal LLC decreased its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 0.2% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 71,029 shares of the company’s stock after selling 170 shares during the period. Johnson & Johnson accounts for 4.0% of WESPAC Advisors SoCal LLC’s investment portfolio, making the stock its 5th largest position. WESPAC Advisors SoCal LLC’s holdings in Johnson & Johnson were worth $11,757,000 as of its most recent filing with the SEC.
A number of other institutional investors have also added to or reduced their stakes in JNJ. Peak Asset Management LLC increased its stake in Johnson & Johnson by 9.3% in the 1st quarter. Peak Asset Management LLC now owns 13,789 shares of the company’s stock worth $2,137,000 after acquiring an additional 1,171 shares during the last quarter. Nisa Investment Advisors LLC increased its stake in Johnson & Johnson by 0.9% in the 1st quarter. Nisa Investment Advisors LLC now owns 748,842 shares of the company’s stock worth $116,071,000 after acquiring an additional 6,836 shares during the last quarter. Vaughan Nelson Investment Management L.P. increased its stake in Johnson & Johnson by 21.8% in the 1st quarter. Vaughan Nelson Investment Management L.P. now owns 903,546 shares of the company’s stock worth $140,050,000 after acquiring an additional 161,687 shares during the last quarter. Tekla Capital Management LLC increased its stake in Johnson & Johnson by 12.8% in the 1st quarter. Tekla Capital Management LLC now owns 721,779 shares of the company’s stock worth $111,876,000 after acquiring an additional 82,100 shares during the last quarter. Finally, Franklin Street Advisors Inc. NC increased its stake in Johnson & Johnson by 0.7% in the 2nd quarter. Franklin Street Advisors Inc. NC now owns 80,179 shares of the company’s stock worth $13,271,000 after acquiring an additional 562 shares during the last quarter. Hedge funds and other institutional investors own 68.40% of the company’s stock.
Insider Activity
In other news, insider William Hait sold 14,698 shares of the firm’s stock in a transaction that occurred on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total value of $2,528,056.00. Following the completion of the transaction, the insider now owns 87,747 shares in the company, valued at approximately $15,092,484. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, insider William Hait sold 14,698 shares of the firm’s stock in a transaction that occurred on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the completion of the transaction, the insider now owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Peter Fasolo sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total value of $3,406,400.00. Following the transaction, the vice president now directly owns 102,696 shares of the company’s stock, valued at approximately $17,491,182.72. The disclosure for this sale can be found here. 0.20% of the stock is currently owned by company insiders.
Johnson & Johnson Trading Up 0.3 %
Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its earnings results on Thursday, July 20th. The company reported $2.80 EPS for the quarter, beating analysts’ consensus estimates of $2.62 by $0.18. The company had revenue of $25.53 billion during the quarter, compared to analysts’ expectations of $24.63 billion. Johnson & Johnson had a return on equity of 36.72% and a net margin of 13.35%. The firm’s revenue for the quarter was up 6.3% compared to the same quarter last year. During the same quarter last year, the business posted $2.59 EPS. On average, analysts forecast that Johnson & Johnson will post 10.02 earnings per share for the current year.
Johnson & Johnson Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Thursday, September 7th. Stockholders of record on Monday, August 28th were paid a $1.19 dividend. This represents a $4.76 dividend on an annualized basis and a dividend yield of 3.02%. The ex-dividend date was Friday, August 25th. Johnson & Johnson’s payout ratio is presently 96.36%.
Analysts Set New Price Targets
JNJ has been the topic of several recent research reports. Morgan Stanley reduced their price objective on Johnson & Johnson from $187.00 to $172.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 31st. Credit Suisse Group increased their price objective on Johnson & Johnson from $170.00 to $175.00 and gave the company a “neutral” rating in a research report on Friday, July 21st. Atlantic Securities increased their price objective on Johnson & Johnson from $167.00 to $170.00 and gave the company a “neutral” rating in a research report on Friday, August 4th. Barclays reduced their price objective on Johnson & Johnson from $175.00 to $158.00 and set an “equal weight” rating on the stock in a research report on Friday, September 8th. Finally, Wells Fargo & Company reduced their price objective on Johnson & Johnson from $195.00 to $186.00 and set an “overweight” rating on the stock in a research report on Thursday, August 31st. Nine investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $171.06.
View Our Latest Report on Johnson & Johnson
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- How to Invest in the Best Canadian Stocks
- How To Find Value Stocks Using This Simple Filtering Method
- Why is the Ex-Dividend Date Significant to Investors?
- MarketBeat Week in Review – 10/2 – 10/6
- How Technical Indicators Can Help You Find Oversold Stocks
- Levi Strauss: A Bottom is in for Steady, Stable Dividend Payer
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
